Artrya (AYA) investor relations material

Executive summary

• Completed technical integration with Cone Health and advanced commercial negotiations with Northeast Georgia and Cone Health, aiming for all three U.S. launch partners to be fully commercial by year-end 2025.

• Achieved first U.S. commercial revenues with successful integration at Tanner Health, following a five-year, $0.6M agreement.

• Raised $80 million (A$80M) in capital, strongly supported by existing and new shareholders, to fund U.S. commercial expansion.

• Salix Coronary Plaque module received FDA clearance in August, nearly 30 days ahead of schedule, enabling U.S. reimbursement of US$950 per scan.

• Built out U.S. leadership and support teams, including a Senior Customer Success Director, accelerating commercial and clinical operations.

Financial highlights

• Cash outflows from operating activities were $6 million (A$6.0M), up from the previous quarter due to increased commercial and regulatory activities, including $830,000 (A$0.8M) in one-off costs.

• Excluding one-off costs, cash outflows from operations were $5.1 million (A$5.1M), down from $5.4 million in the June 2025 quarter.

• Ended September 30 with a cash balance of $62.8 million (A$62.8M); pro forma cash with additional funds would be $82.5 million (A$82.5M).

• Received $60.3 million from the first tranche of placement and expects $14.7 million from the second tranche, plus $5 million from an oversubscribed share purchase plan.

• Estimated 10.5 quarters of funding available at current cash burn rate.

Outlook and guidance

• Near-term priorities include securing commercial agreements with Northeast Georgia and Cone Health, hiring U.S. go-to-market personnel, and earning first commercial revenues from the Salix Coronary Plaque module.

• Full revenue ramp expected with all three modules for the three hospital partners by end of FY2026 and into FY2027.

• SAPPHIRE study to commence in early 2026, targeting broader adoption and clinical validation.

• Targeting break-even position by FY2027, with costs expected to rise slightly as U.S. operations expand.

• U.S. commercial launch to expand in 2026, with additional hospital integrations and revenue growth expected.